Tecumseh Partners is an independent biotechnology advisory firm focused on helping companies navigate the intersection of science, strategy, capital markets, and valuation.

Founded by Hartaj Singh after more than two decades across biotechnology equity research, investing, and the capital markets, Tecumseh Partners brings an analyst’s discipline to complex strategic questions. The approach begins with the underlying science and business, examines the risks before the opportunities, and considers how corporate decisions and execution are ultimately interpreted by investors and other stakeholders.

Our objective is straightforward: help biotechnology companies reduce uncertainty, communicate with greater clarity, and make better-informed strategic decisions—while keeping the needs of patients and caregivers at the center of the analysis.

About Hartaj Singh

Hartaj Singh is the founder of Tecumseh Partners and has more than two decades of experience across biotechnology equity research, investing, and capital markets.

Prior to founding Tecumseh Partners in 2024, Hartaj was a Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. His career has also included biotechnology research roles at BTIG and Lehman Brothers, as well as investing experience at Visium Asset Management. Across these roles, he has evaluated biotechnology companies through multiple market cycles, working at the intersection of scientific innovation, clinical development, corporate strategy, and valuation.

Hartaj holds an MBA from Duke University’s Fuqua School of Business and has graduate training in computational neurobiology.

Hartaj is also the author of Biotech Capital Compass, an independent research publication focused on biotechnology, capital markets, valuation, and the forces shaping the sector. Through BCC, he publishes ongoing analysis designed to help investors and biotechnology operators better understand the relationship between underlying businesses and their expression in the capital markets.

His work at Tecumseh Partners draws on this multidisciplinary background to help biotechnology companies better understand the relationship between scientific and operational execution, investor expectations, capital formation, and long-term value creation.